<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738630</url>
  </required_header>
  <id_info>
    <org_study_id>HX008-II-NMIBC-01</org_study_id>
    <nct_id>NCT04738630</nct_id>
  </id_info>
  <brief_title>Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer</brief_title>
  <official_title>A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With BCG-Unresponsive Non-muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou Hanzhong biomedical co. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou Hanzhong biomedical co. LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008&#xD;
      injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>up to approximately 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) in the Ta/T1 subset</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystectomy-free survival</measure>
    <time_frame>up to approximately 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: HX008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HX008</intervention_name>
    <description>200 mg administered as IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Experimental: HX008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          -  Age ≥ 18 years old, male or female.&#xD;
&#xD;
          -  Predominant histologic component (&gt; 50%) must be urothelial (transitional cell)&#xD;
             carcinoma.&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Score.&#xD;
&#xD;
          -  Histologically-confirmed diagnosis of high risk non-muscle invasive bladder cancer&#xD;
             (T1, high grade Ta and/or carcinoma in situ [CIS]).&#xD;
&#xD;
          -  BCG-unresponsive high risk non-muscle-invasive bladder cancer, BCG-unresponsive&#xD;
             disease as defined as: (a) Persistent or recurrent CIS (+/- recurrent Ta/T1 disease)&#xD;
             within 9 months of receiving adequate BCG (at least five of six doses doses of an&#xD;
             initial induction course plus either at least two of three doses of maintenance&#xD;
             therapy or at least two of six doses of a second induction course); or (b) Recurrent&#xD;
             high-grade Ta/T1 disease within 9 months of completion of adequate BCG (at least five&#xD;
             of six doses of an initial induction course plus either at least two of three doses of&#xD;
             maintenance therapy or at least two of six doses of a second induction course).&#xD;
&#xD;
          -  Patients must be deemed unfit for radical cystectomy by the treating physician or&#xD;
             refuse radical cystectomy.&#xD;
&#xD;
          -  All visible tumor must be completely resected 60 days prior to the first dose of trial&#xD;
             treatment. Patients with T1 tumors must undergo a re-staging transurethral resection&#xD;
             of bladder tumor (TURBT) within 6 weeks after initial TURBT, and re-staging TURBT must&#xD;
             be 60 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  All patients must have had a cystoscopy without papillary tumor and negative urinary&#xD;
             cytology within 21 days prior to the first dose of trial treatment (positive cytology&#xD;
             is allowed in patients with CIS component). A cystoscopy is not needed if the TURBT&#xD;
             falls within 21 days of prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Patients must have had imaging with X-ray for chest, computed tomography (CT) or&#xD;
             magnetic resonance imaging (MRI) for abdomen/pelvis within 90 days prior to the first&#xD;
             dose of trial treatment demonstrating no evidence of metastasis.&#xD;
&#xD;
          -  Willing to provide tissue specimens.&#xD;
&#xD;
          -  Has adequate organ function as defined in the protocol.&#xD;
&#xD;
          -  Male subjects must agree to use effective contraceptives during treatment and for at&#xD;
             least 120 days after the last treatment.&#xD;
&#xD;
          -  Women of childbearing age must have a negative pregnancy test within 72 hours before&#xD;
             the first dose of trial treatment, and agree to use effective contraceptives during&#xD;
             treatment and for at least 120 days after the last treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Muscle-invasive or metastatic urothelial carcinoma.&#xD;
&#xD;
          -  Concurrent extra-vesical (i.e., urethra, ureter, or renal pelvis) non-muscle invasive&#xD;
             transitional cell carcinoma of the urothelium.&#xD;
&#xD;
          -  Patients who had a malignant tumor other than urothelial carcinoma of the bladder&#xD;
             within the first 5 years of enrolment. The following can be included: a. low-risk&#xD;
             localized prostate cancer (staging ≤ T2B, Gleason score ≤7, PSA≤20ng/mL, no recurrence&#xD;
             after treatment (as determined by PSA level)); b. low-risk prostate cancer (T1/ T2A,&#xD;
             Gleason score ≤7, and PSA≤10ng/mL) who were not treated and under observation; c.&#xD;
             patients with very low risk metastasis or death of malignant tumor (5-year metastasis&#xD;
             or death risk&lt; 5%), showed no recurrence after standard treatment, such as cervical&#xD;
             cancer in situ, basal or squamous cell skin cancer, etc.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, or anti-PD-L1, or anti-CTLA-4, or&#xD;
             anti-4-1BB agents.&#xD;
&#xD;
          -  Has received systemic chemotherapy or immunotherapy, or radiation therapy for bladder&#xD;
             cancer.&#xD;
&#xD;
          -  Patients with active autoimmune disease that has required systemic treatment in past 2&#xD;
             years.&#xD;
&#xD;
          -  Has received a major surgery within 4 weeks prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          -  Has a history of testing positive for human immunodeficiency virus (HIV), or known&#xD;
             acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Patients with active chronic hepatitis B or active hepatitis C. Patients with&#xD;
             non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA below the threshold&#xD;
             of the test standard of each center), and cured hepatitis C can be enrolled.&#xD;
&#xD;
          -  Has received system treatment with corticosteroids (dose &gt;10mg/day prednison or other&#xD;
             therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has a history of active tuberculosis.&#xD;
&#xD;
          -  Has a history or current interstitial pneumonia, or current non--infectious&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has uncontrolled systemic disease, such as diabetes or hypertension.&#xD;
&#xD;
          -  Has cardiac dysfunction (grade III-IV according to NYHA) and significant pulmonary&#xD;
             disease (such as shortness of breath at rest or minor activity or the need for oxygen&#xD;
             for any reason) prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Patients with other disease, or metabolic disorder, or abnormal physical examination&#xD;
             or laboratory test, or anticipated to cause complications with trial treatment.&#xD;
&#xD;
          -  Has a severe infection prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has a history of severe allergic reaction to any other monoclonal antibodies.&#xD;
&#xD;
          -  Has participated in other anticancer drug clinical trials within 4 weeks.&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial.&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  According to the judgement of the investigators, there are other factors that may lead&#xD;
             to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dingwei Ye</last_name>
    <phone>34778299</phone>
    <email>dwyeli@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Union Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiquan Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqing Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingwei Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Gou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

